Basel, July 17, 2025 – Anaveon, a global clinical stage, immuno-oncology company, today announced the publication in the Journal for ImmunoTherapy of Cancer (JITC) a paper describing the novel approach of ANV600 to deliver IL-2Rβγ agonism specifically to PD-1+ cells while preserving the binding site for PD-1 checkpoint inhibitors. The findings support the ongoing clinical development of ANV600 as both a monotherapy and a combination therapy in cancer immunotherapy.

For more information, please read the paper titled “ANV600, a novel PD-1 targeted IL-2Rβγ agonist that selectively expands tumor antigen-specific T cells and potentiates PD-1 checkpoint inhibitor therapy,” here.